- Home
- PACB vs ALLO Comparison
PACB vs ALLO Comparison
Compare PACB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PACB | ALLO |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.8M | 597.7M |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PACB | ALLO |
|---|---|---|
| Price | $1.37 | $1.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $1.67 | ★ $8.35 |
| AVG Volume (30 Days) | ★ 5.6M | 4.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $93,468,000.00 | N/A |
| Revenue This Year | $11.32 | N/A |
| Revenue Next Year | $12.14 | $142,416.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.04 | N/A |
| 52 Week Low | $1.07 | $1.04 |
| 52 Week High | $2.73 | $4.46 |
Technical Indicators
Market Signals| Indicator | PACB | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 35.42 |
| Support Level | $1.27 | $1.59 |
| Resistance Level | $1.47 | $1.92 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 59.46 | 6.58 |
Price Performance
Historical ComparisonAbout PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).